- Zacks•10 days ago
Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.
- PR Newswire•11 days agoU.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Feb. 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed biosimilar to Neulasta® (pegfilgrastim), for filing through the 351(k) pathway.
- Zacks•2 months ago
Mylan (MYL) and Biocon Ltd. announced that the FDA had accepted the BLA for their biosimilar version of Herceptin (trastuzumab), MYL-1401O.
BIOCON.NS : Summary for BIOCON INR5 - Yahoo Finance
Biocon Limited (BIOCON.NS)
NSE - NSE Delayed Price. Currency in INR
Add to watchlist
|Day's Range||1,095.90 - 1,137.55|
|52 Week Range||454.85 - 1,138.50|
|PE Ratio (TTM)||19.43|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|